Skip to Content

Royalty Pharma PLC Class A RPRX

Morningstar Rating
$28.77 +0.32 (1.12%)
View Full Chart
Unlock Our Analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

RPRX is trading at a 20% discount.
Price
$28.61
Fair Value
$39.41
Uncertainty
High
1-Star Price
$75.33
5-Star Price
$23.20
Economic Moat
Crpvllg
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RPRX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$28.45
Day Range
$28.2929.08
52-Week Range
$25.9342.84
Bid/Ask
$26.91 / $29.09
Market Cap
$12.85 Bil
Volume/Avg
2.2 Mil / 2.3 Mil

Key Statistics

Price/Earnings (Normalized)
127.36
Price/Sales
5.47
Dividend Yield
2.81%
Dividend Yield (Forward)
2.81%
Total Yield
2.81%

Company Profile

Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Value
Total Number of Employees
75

Valuation

Metric
RPRX
Price/Earnings (Normalized)
127.36
Price/Book Value
2.07
Price/Sales
5.47
Price/Cash Flow
4.53
Price/Earnings
RPRX

Financial Strength

Metric
RPRX
Quick Ratio
13.46
Current Ratio
13.51
Interest Coverage
2.41
Quick Ratio
RPRX

Profitability

Metric
RPRX
Return on Assets (Normalized)
−7.35%
Return on Equity (Normalized)
−20.59%
Return on Invested Capital (Normalized)
−6.95%
Return on Assets
RPRX

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRJqcc$451.0 Bil
VRTX
Vertex Pharmaceuticals IncNngykf$91.3 Bil
REGN
Regeneron Pharmaceuticals IncWmfxrp$89.4 Bil
SGEN
Seagen Inc Ordinary SharesQtrvq$40.7 Bil
MRNA
Moderna IncNycxp$29.8 Bil
ARGX
argenx SE ADRXpdf$27.8 Bil
BNTX
BioNTech SE ADRTsxf$23.5 Bil
ALNY
Alnylam Pharmaceuticals IncNlzjj$21.4 Bil
BMRN
Biomarin Pharmaceutical IncGbyclt$17.6 Bil
INCY
Incyte CorpFkghw$12.3 Bil